Extracellular domain of 4-1BBL enhanced the antitumoral efficacy of peripheral blood lymphocytes mediated by anti-CD3 x anti-Pgp bispecific diabody against human multidrug-resistant leukemia.


Journal Article

Our previous data have shown a significantly higher tumor response to anti-CD3/anti-Pgp bispecific diabody-mediated immunotherapy for P-glycoprotein (Pgp)-overexpressing K562/A02 cells, but a rapid tumor relapse occurred at 1 week after therapy. In an attempt to overcome tumor recurrence, we supplemented the previous therapy with extracellular domain of human 4-1BBL (ex4-1BBL) to regulate the activation of peripheral blood lymphocyte (PBL). As a result, this combination showed enhanced cytotoxicity in vitro and eradicated the multidrug-resistant xenografts of K562/A02 in nude mice. Furthermore, no tumor recurrence was observed within 100 days after the first treatment. Therefore, when used as an adjuvant, ex4-1BBL may improve the outcome of PBL-based immunotherapy.

Full Text

Cited Authors

  • Guo, H; Jiang, W; Liu, W; Gao, Y; Yang, M; Zhou, Y; Wang, J; Qi, J; Cheng, X; Zhu, Z; Yang, C; Xiong, D

Published Date

  • February 2008

Published In

Volume / Issue

  • 251 / 2

Start / End Page

  • 102 - 108

PubMed ID

  • 18482719

Pubmed Central ID

  • 18482719

Electronic International Standard Serial Number (EISSN)

  • 1090-2163

International Standard Serial Number (ISSN)

  • 0008-8749

Digital Object Identifier (DOI)

  • 10.1016/j.cellimm.2008.04.006


  • eng